Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market. Lilly’s ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight ... The test drug combines semaglutide, ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...